2024澳门原料网站-免费完整资料

Be the most trusted biotech company

2020-04-23

Henlius Receives EU GMP Certificate for HLX02 (Trastuzumab for Injection)
2020-04-23

First Patient in Overseas Trial Site Dosed in the Multi-centre International Phase 3 Study of Henlius Anti-PD-1 mAb for the Treatment of Lung Cancer
2020-04-08

Henlius Received IND Approval for Its Ipilimumab Biosimilar HLX13 from NMPA
2020-03-31

Henlius Products Licensed out to Nearly 100 Countries and Regions
2020-03-31

Henlius Novel Anti-EGFR Monoclonal Antibody Demonstrated Favorable Safety and Tolerability Profile in Its Phase 1 Clinical Study
2020-03-23

Open Your Mind, Unleash Your Potential | Exclusive Interview of Henlius Senior Vice President of Technical Operations, Dr. Simon Hsu
2020-03-11

First Patient Dosed in Phase 2 Clinical Trial of Henlius Anti-PD-1 mAb in Combination with Chemotherapy in Patients with Advanced Cervical Cancer
2020-03-09

Henlius Received Acceptance Notification for Clinical Trial Application from NMPA for its Denosumab Biosimilar HLX14
2020-03-04

First Patient Dosed in Phase 1 Study of Henlius Innovative Anti-c-MET Monoclonal Antibody HLX55 for the Treatment of Advanced Solid Tumours